Japan and India eye each other for new pharma deals

By Kirsty Barnes

- Last updated on GMT

Related tags: Pharmaceutical industry, India

The Japanese pharmaceutical industry is eyeing India as a new hub
to conduct its contract manufacturing and clinical trials - India
is thirsty for new Japanese investment.

In recent times India has turned a corner and Western pharma firms who once shied away are now flocking to the country to either outsource various business functions or set up infrastructure and take advantage of India's burgeoning, low cost pharmaceutical industry - Japan has indicated it does not want to be left out.

As a reuslt, Ram Vilas Paswan, India's Minister for Steel, Fertilisers and Chemicals, led a six-day delegation tour of Japan last week to "to explore the vast potential and expertise offered by the Japanese pharmaceutical and chemical majors."

While in Japan, Paswan met with leading representatives of the country's pharma industry and visited the premises of Japanese pharma giants Eisai and Mitsbishi Corporation in order to discuss new cooperation agreements between the two countries.

Meetings with the Minister of Foreign Affairs and the Minister of Economy, Trade and Industry of Japan were also on the agenda and according to Paswan, initial talks were promising.

Eisai Chemicals expressed its intention to set up a new manufacturing unit and R&D facility in India, at either Vishakhapatnam or Indore, Paswan told reporters in Tokyo.

In addition, Paswan said Mitsubishi Chemicals had announced a Rs1665 crore (€285.1m) plan to expand the manufacturing capacity of purified teraphthalic acid (pta) - a petrochemical used in plastic products - from 470,000 tonnes to 1, 270,000 tonnes at its facility in Haldia.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more